Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis

Table 1 Patient characteristics

Characteristic	n	%
Sex
Male	2	2.0
Female	102	98.0
Age at diagnosis (yr)
Median (range)	58.9	(32.5–83.0)
< 40	8	7.7
40-59	51	49.0
≥ 60	45	43.3
Histology
Invasive ductal carcinoma	84	80.8
Lobular carcinoma	14	13.4
Other	6	5.8
Tumor laterality
Bilateral	5	4.8
Left	45	43.3
Right	54	51.9
Tumor quadrant
Inner	16	15.4
Central	14	13.5
Outer	64	61.5
Other	10	9.6
Clinical T4 stage	8	7.7
Tumor size
0-20 mm (TNM T1 classification[16])	37	35.6
> 20 mm (one imputed as 30 mm)	67	63.5
Stage
I	18	17.6
IIA	28	27.5
IIB	18	17.6
III	34	33.3
IV	4	3.9
Unknown	2	–
Grade
1	29	29.0
2	42	42.0
3	29	29.0
Unknown	4	–
Hormone receptor status
ER+/PR+	67	64.4
ER–/PR–	20	19.2
Other	17	16.3
Events
Loco-regional recurrence	4 of 104	3.8
Distant metastases	31 of 104	29.8
Death from any cause	28 of 104	26.9

ER+: Estrogen receptor-positive; ER-: Estrogen receptor-negative; PR+: Progesterone receptor-positive; PR-: Progesterone receptor-negative.